Leuven — Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG (histidine-rich glycoprotein) prevents metast…
Salt Lake City, September 17, 2010 — Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of al…
Antibiotics can work miracles, knocking out common infections like bronchitis and tonsillitis. But according to the Center for Disease Control, each year 90,000 people in the U.S. die of drug-resistant “superbugs” ― bacteria like Staphylococcu…
The Department of Computer Science and Technology, Peking University, Beijing, China, has shown that a novel dynamic memory mapping (DMM) model brings about additional flexibility to virtual resource management, leading to the feature-adjustable des…
In a study of egg cells using time-lapse microscopy, researchers at the University of California, San Diego School of Medicine and the Ludwig Institute for Cancer Research have discovered an unusual property of meiosis — cell division that prod…
The Cepheid period-luminosity relation that claims stars with long periods are brighter than those with short periods including measurements of the distance to the star based on the Baade-Wesselink method are placed in question by cosmic dust.
A drug similar to thalidomide has been found to be promising with fewer side effects for treating patients with recurrent multiple myeloma, an incurable form of bone marrow cancer, according to early data from a clinical study. The drug, an analog of thalidomide, was developed to be more potent than thalidomide, while reducing some of thalidomide’s dose limiting side effects. Laboratory studies have shown that CC-5013 not only kills myeloma cells by triggering their innate self-destruct mechanism but also inhibits the myeloma cells ability to localize and grow in the bone marrow. Moreover, it appears to have anti-angiogenic effects and stimulates the immune system to attack myeloma.